AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antiviral Therapies Promise Significant Treatment Rewards.(Brief Article)
2002 JAN 30 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., announced the publication of "Hepatitis B Virus," a new study that explains why, despite considerable progress in the prevention and treatment of this disease, the hepatitis B virus (HBV) market remains open to innovation, particularly for therapies to treat chronically infected patients.
This study evaluated the therapeutic and commercial potential of promising agents and vaccines expected to fill this gap during the next decade.
Antiviral agents are the most promising drugs in development for the treatment of chronic HBV infection. They suppress HBV DNA replication and reduce the risk of liver damage over the course of chronic infection. The 1998 launch of GlaxoSmithKline's lamivudine, the first antiviral agent approved for chronic HBV infection, sparked a revolutionary change in the treatment of this disease. Lamivudine is administered orally, is relatively inexpensive, and has no apparent serious side effects, resulting in the widespread use of lamivudine for chronic HBV infection.
Consequently, lamivudine has taken considerable market share from interferon-(alpha), previously the only drug approved for HBV. However, ...
- ANALYST: RESISTANCE `A COMPLICATED ISSUE' FDA PANEL ADVISES APPROVAL OF EPIVIR...
- Magazine article from: BIOWORLD Today October 8, 1998 700+ words
...million people worldwide with chronic HBV infection, 1 million of whom are in the...in controlled studies of 967 chronic HBV patients and resulted in improved...75 percent of the world's chronic HBV carriers live in Southeast Asia...
- Chronic HBV seen in 9% of Asian immigrants.(Infectious Diseases)
- Magazine article from: Family Practice News Wendling, Patrice April 15, 2007 700+ words
...51,000 new hepatitis B infections in the U.S. HBV infection is associated with a 25% risk of death if it is...liver cancer, because of their high prevalence of chronic HBV infection "Given the serious medical implications of this...
- XTL Biopharmaceuticals Presents Interim Phase I Data on First Combination...
- Press release article from: PR Newswire October 30, 2000 700+ words
...Phase I trial evaluated the safety, tolerability and efficacy of single-dose XTL-001 for the treatment of chronic HBV infection over a 16 week follow-up period (treatment with multi-dose XTL- 001 is planned as another arm of the trial...
- Occult HBV infection in endemic areas doesn't affect clinical outcome of HCV+.
- Newspaper article from: Hepatitis Weekly January 13, 2003 700+ words
...negative for serological markers of HBV infection." "In patients with chronic...infection, the prevalence of occult HBV infection did not parallel the severity...patients with and without occult HBV infection (38% versus 39%)." Kao...
- HBV genotype A prevails in Japanese patients with acute HBV infection.
- Newspaper article from: Hepatitis Weekly January 6, 2003 700+ words
...show. "Acute hepatitis B virus (HBV) infection was diagnosed in 57 adults admitted...seven patients with acute prolonged HBV infection, and four of them responded by clearing...adult patients with acute prolonged HBV infection, except in those infected with HBV...
- Enzo Biochem Announces Results of Phase I Treatment for HBV Infection; Positive...
- Press release article from: Business Wire October 31, 2000 700+ words
...tupaia, a small prosimian primate, infected with human HBV. HBV infection results in a wide range of clinical manifestations ranging...EHT899, Enzo's therapy for liver inflammation caused by HBV infection. The preclinical animal studies were carried out at the...
- Coinfecting viruses don't change the kinetics of acute HBV infection.
- Newspaper article from: Virus Weekly April 1, 2003 700+ words
2003 APR 1 - (NewsRx.com & NewsRx.net) -- Coinfecting viruses don't change the kinetics of acute HBV infection. "The kinetics of hepatitis B virus (HBV) and its surface antigen (HBsAg) during acute hepatitis has not yet been...
- Treatment for HBV infection in HIV patients reviewed.
- Newspaper article from: Anti-Infectives Week April 12, 2004 700+ words
2004 APR 12 - (NewsRx.com & NewsRx.net) -- The treatment guidelines for patients infected with HIV and HBV have been reviewed. "Among human immunodeficiency virus (HIV)-infected individuals, the prevalence of hepatitis B surface antigen (HBsAg) seropositivity is approximately 10-fold higher
